Botox Cosmetic Approved for Forehead Lines

Botox Cosmetic Effective for Glabella, Crow's Feet and Forehead Lines

The U.S. Food and Drug Administration has granted Allergan’s Botox Cosmetic approval for its third indication, the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults. This approval makes the brand the first neurotoxin indicated for three facial treatment areas: forehead lines, crow’s feet lines and glabellar lines.

Modulating Expression

Physicians share their techniques for obtaining better longevity and more natural-looking results with botulinum toxins.
Improving longevity and outcomes with neurotoxins

What started as a simple injection to lessen crow’s feet has blossomed into a multibillion dollar market and given rise to today’s medical aesthetics industry. With nearly 30 years of experience and a growing variety of botulinum toxins entering the market, the current focus in neuromodulation is on extending the longevity of results and delivering natural-looking outcomes.

Comparing Three Botulinum Toxins

Comparing Three Botulinum Toxins

A study in Plastic and Reconstructive Surgery (May 2016) used digital image correlation to compare dynamic strain reduction between three U.S. Food and Drug Administration (FDA)-approved formulations of botulinum toxin: onabotulinumtoxinA (Botox, Allergan), abobotulinumtoxinA (Dysport, Galderma) and incobotulinumtoxinA (Xeomin, Merz).

Skin Care: Xeomin

Main Image: 

Xeomin botulinum toxin type A is FDA approved for the treatment of moderate to severe glabella lines. The toxin comes in powder form and does not require refrigeration. In addition, the company employs a proprietary manufacturing process that isolates the therapeutic component of the toxin and removes the accessory proteins. Contact: 866.862.1211,

No, don't share this with BeautyEtc
Article free tagging: 

AbobotulinumtoxinA may offer faster onset of action and longer duration of results

A split-face study comparing the onset of action, change in degree of wrinkles, patient satisfaction, duration of effect and adverse effects of OnabotulinumtoxinA (ONA; Botox, Allergan, and AbobotulinumtoxinA (ABO; Dysport, Valeant Pharmaceuticals) has revealed subtle differences between the two popular injectables. Ramtin Kassir, MD, et al, treated 85 patients aged 18-75 with moderate to severe wrinkles in either the glabellar or crow’s feet area, or both. Patients who had conditions that would interefere with the assessment of wrinkles were excluded.

Botulinum Toxin Reduces Sebum Production

Botulinum Toxin Reduces Sebum Production

Botulinum toxin injections can reduce sebum production in the forehead region for three months following treatment. Researchers Amy E. Rose, MD, and David J. Goldberg, MD, treated 25 patients with oily skin using intradermal injections of botulinum toxins in the forehead. Sebum production was measured at baseline and at one week, one month, two months and three months post-treatment using a sebometer. Sebum production was decreased significantly from baseline at each time interval, and 21 of the 25 patients reported that they were satisfied with the treatment.

Neurotoxins May Aid in Dermal Remodeling

Intradermal injections of botulinum toxin type A (BoNT) may offer some dermal remodeling effects, according to researchers at Chungnam National University’s Department of Plastic and Reconstructive Surgery in South Korea. S.H. Oh, et al, measured procollagen type I carboxy-terminal peptide (PIP) in dermal fibroblasts grown in the presence of BoNT, using an enzyme-linked immunosorbent assay. Collagen production was monitored using Western blotting. The researchers also measured matrix metalloproteinase using gelatin zymography.